Brean Capital Starts C.R. Bard, Inc. (BCR) at Hold
Tweet
Share
E-mailGet Alerts BCR Hot Sheet
Price: $331.24 --0%
Rating Summary:
10 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Brean Capital initiates coverage on C.R. Bard, Inc. (NYSE: BCR) with a Hold.
The firm comments, "BCR is a leading hospital supply name, with market leading share in its four businesses (Urology, Specialty Surgery, Oncology and peripheral Vascular). In our view, three out of those four businesses are maturing, Oncology being the exception, making BCR more vulnerable to competition, hospital price and volume pressure. As a result, the company has seen organic revenue growth drop to low single digits, and we don’t see a clear catalyst for acceleration until at least 2014, when investments, notably, Lutonix, kick in. Until then, the company looks to continue to invest, though much of that will be financed with an expected $1 billion payment (plus ongoing royalties) from the Gore settlement - by mid 2013."
For an analyst ratings summary and ratings history on C.R. Bard, Inc. click here. For more ratings news on C.R. Bard, Inc. click here.
Shares of C.R. Bard, Inc. closed at $97.28 yesterday.
The firm comments, "BCR is a leading hospital supply name, with market leading share in its four businesses (Urology, Specialty Surgery, Oncology and peripheral Vascular). In our view, three out of those four businesses are maturing, Oncology being the exception, making BCR more vulnerable to competition, hospital price and volume pressure. As a result, the company has seen organic revenue growth drop to low single digits, and we don’t see a clear catalyst for acceleration until at least 2014, when investments, notably, Lutonix, kick in. Until then, the company looks to continue to invest, though much of that will be financed with an expected $1 billion payment (plus ongoing royalties) from the Gore settlement - by mid 2013."
For an analyst ratings summary and ratings history on C.R. Bard, Inc. click here. For more ratings news on C.R. Bard, Inc. click here.
Shares of C.R. Bard, Inc. closed at $97.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
